NKTR Stock Summary and Trading Ideas (Nektar Therapeutics | NASDAQ:NKTR)

Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar Therapeutics trades on the NASDAQ stock market under the symbol NKTR.

As of February 13, 2026, NKTR stock price climbed to $71.33 with 2,082,682 million shares trading.

NKTR has a beta of 3.61, meaning it tends to be more sensitive to market movements. NKTR has a correlation of 0.16 to the broad based SPY ETF.

NKTR has a market cap of $1.45 billion. This is considered a Small Cap stock.

Last quarter Nektar Therapeutics reported $12 million in Revenue and -$1.87 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.94.

In the last 3 years, NKTR traded as high as $73.37 and as low as $6.19.

The top ETF exchange traded funds that NKTR belongs to (by Net Assets): VTI, VXF, XPH, SCHA, PRFZ.

NKTR has outperformed the market in the last year with a price return of +433.2% while the SPY ETF gained +13.0%. NKTR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +32.2% and +91.1%, respectively, while the SPY returned +1.7% and -1.5%, respectively.

NKTR support price is $66.45 and resistance is $75.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NKTR shares will trade within this expected range on the day.